Your browser is no longer supported. Please, upgrade your browser.
Aileron Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own31.56% Shs Outstand39.32M Perf Week36.30%
Market Cap68.15M Forward P/E- EPS next Y-0.51 Insider Trans334.46% Shs Float27.84M Perf Month89.75%
Income-23.40M PEG- EPS next Q-0.12 Inst Own14.40% Short Float4.24% Perf Quarter-5.15%
Sales- P/S- EPS this Y44.10% Inst Trans0.04% Short Ratio0.44 Perf Half Y75.24%
Book/sh0.32 P/B5.75 EPS next Y13.60% ROA-98.30% Target Price- Perf Year130.72%
Cash/sh0.38 P/C4.80 EPS next 5Y2.10% ROE-170.40% 52W Range0.25 - 2.47 Perf YTD76.92%
Dividend- P/FCF- EPS past 5Y-1.80% ROI- 52W High-25.51% Beta3.11
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low636.00% ATR0.17
Employees13 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)69.85 Volatility15.65% 10.25%
OptionableNo Debt/Eq0.02 EPS Q/Q54.20% Profit Margin- Rel Volume2.12 Prev Close1.95
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume2.66M Price1.84
Recom1.40 SMA2045.45% SMA5060.92% SMA20067.10% Volume5,654,311 Change-5.64%
Jul-24-17Initiated William Blair Outperform
Jul-24-17Initiated Jefferies Buy $20
Jul-24-17Initiated BofA/Merrill Buy $19
Jan-11-21 06:30AM  
Jan-06-21 09:30AM  
Dec-23-20 03:41AM  
Dec-21-20 08:00AM  
Dec-14-20 08:32AM  
Dec-01-20 10:12AM  
Nov-29-20 08:33PM  
Nov-24-20 08:28AM  
Nov-19-20 10:02AM  
Nov-12-20 07:03PM  
Oct-24-20 04:35AM  
Oct-20-20 09:24AM  
Oct-13-20 08:30AM  
Oct-12-20 07:00AM  
Sep-21-20 06:07PM  
Sep-10-20 08:45AM  
Aug-25-20 01:25PM  
Aug-05-20 04:10PM  
Aug-04-20 03:31PM  
Aug-03-20 08:10AM  
Jun-29-20 08:30AM  
Jun-12-20 11:42AM  
Jun-10-20 09:54AM  
Jun-04-20 09:15AM  
Jun-03-20 04:01PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-27-20 08:30AM  
May-11-20 08:30AM  
Apr-22-20 08:30AM  
Mar-30-20 04:16PM  
Dec-20-19 05:45PM  
Dec-19-19 06:07AM  
Dec-18-19 08:30AM  
Nov-07-19 07:30AM  
Oct-31-19 08:30AM  
Oct-29-19 08:00AM  
Oct-21-19 08:00AM  
Oct-16-19 08:30AM  
Sep-28-19 07:30AM  
Sep-24-19 05:00PM  
Sep-19-19 07:24AM  
Sep-09-19 08:00AM  
Sep-03-19 05:10PM  
Aug-06-19 04:10PM  
Jul-30-19 07:03PM  
Jul-17-19 02:38PM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
May-30-19 08:00AM  
May-08-19 04:57PM  
May-01-19 06:31PM  
Apr-03-19 12:15PM  
Mar-29-19 09:00AM  
Mar-04-19 09:00AM  
Feb-01-19 02:31PM  
Jan-29-19 09:25AM  
Jan-16-19 12:47PM  
Dec-21-18 11:33AM  
Dec-04-18 09:13AM  
Nov-28-18 10:22AM  
Nov-27-18 08:00AM  
Nov-19-18 08:25AM  
Nov-07-18 04:10PM  
Nov-05-18 04:05PM  
Nov-01-18 04:05PM  
Oct-30-18 04:05PM  
Oct-19-18 08:00AM  
Sep-06-18 09:00AM  
Aug-07-18 04:15PM  
Aug-02-18 07:00AM  
Jul-31-18 07:00AM  
May-29-18 07:00AM  
May-22-18 05:00AM  
May-15-18 04:05PM  
May-09-18 04:03PM  
Apr-11-18 04:05PM  
Apr-02-18 04:09PM  
Mar-28-18 07:00AM  
Mar-19-18 07:00AM  
Dec-11-17 04:30PM  
Nov-09-17 04:18PM  
Nov-01-17 09:19AM  
Oct-05-17 06:40AM  
Sep-19-17 07:00AM  
Aug-24-17 07:00AM  
Aug-10-17 04:11PM  
Aug-03-17 07:00AM  
Jul-19-17 09:21AM  
Jul-07-17 12:46PM  
Jul-03-17 01:02PM  
Jun-28-17 10:06PM  
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Satter Muneer ASee RemarksJan 08Buy1.109,000,0009,900,00016,609,449Jan 08 04:15 PM
Ambros Reinhard J.DirectorJun 15Buy1.225,8007,0765,800Jun 17 04:31 PM
Satter Muneer ADirectorJun 08Buy1.103,700,0004,070,0007,609,449Jun 09 08:22 PM
VON RICKENBACH JOSEF HDirectorJun 08Buy1.10227,272249,999445,460Jun 09 08:23 PM